Chun-Yang Fan
Concepts (278)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 14 | 2010 | 336 | 1.780 |
Why?
| Carcinoma, Squamous Cell | 15 | 2010 | 385 | 1.700 |
Why?
| DNA Methylation | 13 | 2009 | 575 | 1.180 |
Why?
| DNA Glycosylases | 5 | 2011 | 22 | 1.120 |
Why?
| Gene Silencing | 7 | 2009 | 129 | 1.100 |
Why?
| Promoter Regions, Genetic | 11 | 2009 | 520 | 1.070 |
Why?
| DNA Repair | 5 | 2008 | 203 | 0.540 |
Why?
| Mitochondria | 3 | 2011 | 490 | 0.530 |
Why?
| Adaptor Proteins, Signal Transducing | 5 | 2009 | 208 | 0.510 |
Why?
| Polymerase Chain Reaction | 11 | 2009 | 531 | 0.490 |
Why?
| Kidney Neoplasms | 2 | 2008 | 197 | 0.490 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2007 | 164 | 0.480 |
Why?
| DNA, Neoplasm | 10 | 2008 | 171 | 0.480 |
Why?
| Nuclear Proteins | 5 | 2009 | 253 | 0.480 |
Why?
| Neoplasm Proteins | 4 | 2005 | 360 | 0.430 |
Why?
| Laryngeal Neoplasms | 3 | 2007 | 55 | 0.410 |
Why?
| CpG Islands | 3 | 2008 | 104 | 0.390 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2009 | 232 | 0.380 |
Why?
| Lung Neoplasms | 2 | 2007 | 643 | 0.360 |
Why?
| Microsatellite Instability | 1 | 2009 | 20 | 0.360 |
Why?
| Fatty Liver | 1 | 2011 | 129 | 0.360 |
Why?
| Immunohistochemistry | 7 | 2012 | 1090 | 0.340 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 25 | 0.340 |
Why?
| Mitochondrial Proteins | 2 | 2007 | 121 | 0.340 |
Why?
| Port-Wine Stain | 1 | 2008 | 14 | 0.330 |
Why?
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2005 | 10 | 0.320 |
Why?
| Oxygen | 1 | 2011 | 361 | 0.320 |
Why?
| Genes, p16 | 3 | 2005 | 9 | 0.310 |
Why?
| N-Glycosyl Hydrolases | 1 | 2007 | 6 | 0.300 |
Why?
| Lymph Nodes | 2 | 2007 | 284 | 0.300 |
Why?
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2007 | 16 | 0.300 |
Why?
| Carcinoma, Renal Cell | 1 | 2008 | 120 | 0.300 |
Why?
| DNA, Mitochondrial | 4 | 2011 | 186 | 0.290 |
Why?
| Mitochondria, Liver | 1 | 2007 | 86 | 0.290 |
Why?
| Skin | 3 | 2010 | 469 | 0.290 |
Why?
| Aged | 15 | 2011 | 10060 | 0.290 |
Why?
| Adenoma | 1 | 2008 | 142 | 0.280 |
Why?
| Proteoglycans | 2 | 2003 | 96 | 0.280 |
Why?
| Cisplatin | 3 | 2007 | 351 | 0.280 |
Why?
| Fibroma | 1 | 2006 | 41 | 0.270 |
Why?
| Membrane Glycoproteins | 2 | 2003 | 270 | 0.250 |
Why?
| Aged, 80 and over | 8 | 2009 | 3431 | 0.250 |
Why?
| Survival Analysis | 5 | 2009 | 736 | 0.250 |
Why?
| Liver | 1 | 2011 | 1226 | 0.250 |
Why?
| Middle Aged | 16 | 2011 | 13082 | 0.250 |
Why?
| Carcinoma, Hepatocellular | 1 | 2007 | 203 | 0.250 |
Why?
| Ataxia Telangiectasia | 1 | 2004 | 5 | 0.240 |
Why?
| Salivary Ducts | 1 | 2003 | 5 | 0.240 |
Why?
| DNA Repair Enzymes | 1 | 2004 | 50 | 0.240 |
Why?
| Prognosis | 7 | 2007 | 2126 | 0.240 |
Why?
| Salivary Gland Neoplasms | 1 | 2003 | 24 | 0.240 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2003 | 37 | 0.230 |
Why?
| Humans | 36 | 2013 | 54391 | 0.230 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 85 | 0.230 |
Why?
| Liver Neoplasms | 1 | 2007 | 352 | 0.220 |
Why?
| Obesity | 1 | 2011 | 1203 | 0.210 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2013 | 84 | 0.210 |
Why?
| Adult | 14 | 2011 | 14207 | 0.210 |
Why?
| Female | 22 | 2012 | 28471 | 0.200 |
Why?
| Male | 21 | 2012 | 27347 | 0.200 |
Why?
| Epigenesis, Genetic | 1 | 2004 | 399 | 0.190 |
Why?
| Transcription Factors | 1 | 2003 | 622 | 0.180 |
Why?
| Skin Transplantation | 2 | 2010 | 50 | 0.180 |
Why?
| Antineoplastic Agents | 2 | 2010 | 1300 | 0.170 |
Why?
| Carrier Proteins | 4 | 2005 | 360 | 0.160 |
Why?
| Skin Neoplasms | 4 | 2008 | 532 | 0.160 |
Why?
| Tumor Suppressor Proteins | 2 | 2011 | 141 | 0.160 |
Why?
| Loss of Heterozygosity | 2 | 2008 | 97 | 0.160 |
Why?
| Survival Rate | 3 | 2009 | 954 | 0.150 |
Why?
| DNA Damage | 2 | 2011 | 357 | 0.150 |
Why?
| Neoplasm Invasiveness | 4 | 2007 | 294 | 0.140 |
Why?
| Ki-67 Antigen | 2 | 2011 | 63 | 0.130 |
Why?
| Graft Survival | 3 | 2011 | 165 | 0.130 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 39 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 674 | 0.120 |
Why?
| Immunoenzyme Techniques | 4 | 2013 | 166 | 0.120 |
Why?
| Cadherins | 2 | 2005 | 72 | 0.120 |
Why?
| Algorithms | 2 | 2008 | 697 | 0.120 |
Why?
| Keratosis | 2 | 2003 | 14 | 0.120 |
Why?
| Prostatic Neoplasms | 2 | 2008 | 421 | 0.120 |
Why?
| Thyroid Neoplasms | 2 | 2007 | 162 | 0.110 |
Why?
| Receptors, Cell Surface | 1 | 2013 | 130 | 0.110 |
Why?
| Carcinoma in Situ | 2 | 2003 | 74 | 0.110 |
Why?
| Arteriovenous Malformations | 1 | 2013 | 66 | 0.110 |
Why?
| Lymphangioma, Cystic | 1 | 2011 | 9 | 0.110 |
Why?
| Laryngectomy | 3 | 2007 | 28 | 0.100 |
Why?
| Base Sequence | 2 | 2004 | 719 | 0.100 |
Why?
| Leukoplakia, Oral | 1 | 2011 | 8 | 0.100 |
Why?
| Aminolevulinic Acid | 1 | 2011 | 10 | 0.100 |
Why?
| Lasers, Dye | 1 | 2011 | 10 | 0.100 |
Why?
| Endothelium, Lymphatic | 1 | 2011 | 13 | 0.100 |
Why?
| Photosensitizing Agents | 1 | 2011 | 24 | 0.100 |
Why?
| Antigens, CD | 1 | 2013 | 242 | 0.100 |
Why?
| Lymphatic Abnormalities | 1 | 2011 | 22 | 0.100 |
Why?
| Wound Healing | 2 | 2010 | 228 | 0.100 |
Why?
| Propranolol | 1 | 2012 | 78 | 0.100 |
Why?
| Photochemotherapy | 1 | 2011 | 37 | 0.100 |
Why?
| Microtubule-Associated Proteins | 1 | 2011 | 78 | 0.100 |
Why?
| Cell Line, Tumor | 4 | 2010 | 1551 | 0.100 |
Why?
| Homeodomain Proteins | 1 | 2011 | 82 | 0.100 |
Why?
| Drug Resistance, Multiple | 1 | 2010 | 20 | 0.100 |
Why?
| Taxoids | 1 | 2010 | 45 | 0.100 |
Why?
| Laser Therapy | 1 | 2011 | 91 | 0.100 |
Why?
| Hemangioma | 1 | 2012 | 83 | 0.100 |
Why?
| Biopsy | 3 | 2011 | 692 | 0.100 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 60 | 0.090 |
Why?
| Gene Deletion | 1 | 2011 | 293 | 0.090 |
Why?
| Neoplasm Staging | 3 | 2007 | 805 | 0.090 |
Why?
| Follow-Up Studies | 4 | 2011 | 2390 | 0.090 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2010 | 868 | 0.090 |
Why?
| Mice, Transgenic | 1 | 2011 | 658 | 0.080 |
Why?
| Paraffin Embedding | 1 | 2008 | 56 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2011 | 1647 | 0.080 |
Why?
| Drug Resistance, Neoplasm | 1 | 2010 | 309 | 0.080 |
Why?
| Sulfites | 1 | 2008 | 2 | 0.080 |
Why?
| Microsatellite Repeats | 1 | 2008 | 46 | 0.080 |
Why?
| Neoplasm Seeding | 1 | 2008 | 5 | 0.080 |
Why?
| Chordoma | 1 | 2008 | 10 | 0.080 |
Why?
| Recurrent Laryngeal Nerve | 1 | 2007 | 20 | 0.080 |
Why?
| Laryngeal Nerves | 1 | 2007 | 19 | 0.080 |
Why?
| Blood Glucose | 1 | 2011 | 489 | 0.080 |
Why?
| Skull Base Neoplasms | 1 | 2008 | 23 | 0.080 |
Why?
| Receptors, Thyrotropin | 1 | 2007 | 7 | 0.080 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2005 | 62 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 1060 | 0.080 |
Why?
| Animals | 8 | 2011 | 14409 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 2 | 2005 | 96 | 0.080 |
Why?
| Symporters | 1 | 2007 | 18 | 0.080 |
Why?
| Methylation | 2 | 2007 | 130 | 0.080 |
Why?
| Image Enhancement | 1 | 2007 | 56 | 0.080 |
Why?
| Pattern Recognition, Automated | 1 | 2007 | 45 | 0.080 |
Why?
| Mice | 4 | 2011 | 6428 | 0.080 |
Why?
| Precancerous Conditions | 1 | 2008 | 93 | 0.080 |
Why?
| Prostate | 1 | 2008 | 123 | 0.080 |
Why?
| Cell Proliferation | 1 | 2011 | 1097 | 0.080 |
Why?
| Transgenes | 1 | 2007 | 55 | 0.070 |
Why?
| Carcinoma, Papillary | 1 | 2007 | 65 | 0.070 |
Why?
| Risk Factors | 3 | 2008 | 3937 | 0.070 |
Why?
| Cell Nucleus | 1 | 2007 | 203 | 0.070 |
Why?
| Neoplasm Recurrence, Local | 2 | 2008 | 645 | 0.070 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2007 | 119 | 0.070 |
Why?
| Syndecans | 2 | 2003 | 43 | 0.070 |
Why?
| Child, Preschool | 3 | 2012 | 4158 | 0.070 |
Why?
| Artificial Intelligence | 1 | 2007 | 85 | 0.070 |
Why?
| MicroRNAs | 1 | 2010 | 386 | 0.070 |
Why?
| Protein Transport | 1 | 2007 | 195 | 0.070 |
Why?
| Syndecan-1 | 2 | 2003 | 82 | 0.070 |
Why?
| Child | 5 | 2012 | 7368 | 0.070 |
Why?
| RNA, Messenger | 2 | 2007 | 1203 | 0.070 |
Why?
| Genomics | 1 | 2008 | 313 | 0.070 |
Why?
| Adenomatous Polyposis Coli Protein | 1 | 2005 | 4 | 0.070 |
Why?
| Receptors, Atrial Natriuretic Factor | 1 | 2005 | 6 | 0.070 |
Why?
| Atrial Natriuretic Factor | 1 | 2005 | 24 | 0.070 |
Why?
| Ear, Inner | 1 | 2005 | 18 | 0.070 |
Why?
| Guanine | 1 | 2004 | 42 | 0.060 |
Why?
| Cell Physiological Phenomena | 1 | 2004 | 4 | 0.060 |
Why?
| Melanoma | 1 | 2008 | 313 | 0.060 |
Why?
| Cytochromes c | 1 | 2003 | 41 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2005 | 198 | 0.060 |
Why?
| Salivary Proteins and Peptides | 1 | 2003 | 9 | 0.060 |
Why?
| Statistics as Topic | 1 | 2003 | 102 | 0.060 |
Why?
| Base Pair Mismatch | 1 | 2003 | 24 | 0.060 |
Why?
| Isoenzymes | 1 | 2003 | 177 | 0.060 |
Why?
| Tunica Intima | 1 | 2003 | 52 | 0.060 |
Why?
| Adenocarcinoma, Follicular | 1 | 2003 | 8 | 0.060 |
Why?
| DNA Adducts | 1 | 2004 | 162 | 0.060 |
Why?
| Adenocarcinoma, Papillary | 1 | 2003 | 10 | 0.060 |
Why?
| Adenoma, Oxyphilic | 1 | 2003 | 17 | 0.060 |
Why?
| Cell Count | 1 | 2003 | 181 | 0.050 |
Why?
| Keratoacanthoma | 1 | 2002 | 8 | 0.050 |
Why?
| Retrospective Studies | 4 | 2007 | 6459 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2005 | 462 | 0.050 |
Why?
| Collagen | 1 | 2003 | 223 | 0.050 |
Why?
| Lung | 1 | 2005 | 508 | 0.050 |
Why?
| Renal Dialysis | 1 | 2003 | 193 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2003 | 179 | 0.050 |
Why?
| Combined Modality Therapy | 4 | 2004 | 693 | 0.050 |
Why?
| Alcohol Drinking | 1 | 2003 | 259 | 0.050 |
Why?
| Molecular Sequence Data | 1 | 2003 | 980 | 0.050 |
Why?
| Blood Platelets | 1 | 2003 | 268 | 0.050 |
Why?
| Blotting, Western | 2 | 2013 | 684 | 0.050 |
Why?
| Cohort Studies | 1 | 2005 | 1546 | 0.050 |
Why?
| Prevalence | 1 | 2004 | 1025 | 0.050 |
Why?
| Adolescent | 2 | 2012 | 6900 | 0.050 |
Why?
| Tomography, X-Ray Computed | 1 | 2006 | 1222 | 0.050 |
Why?
| Smoking | 1 | 2003 | 552 | 0.040 |
Why?
| Random Allocation | 2 | 2010 | 312 | 0.040 |
Why?
| Quality of Life | 1 | 2004 | 924 | 0.040 |
Why?
| Electrophoresis, Agar Gel | 2 | 2008 | 12 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 922 | 0.040 |
Why?
| Hyperplasia | 2 | 2008 | 107 | 0.030 |
Why?
| Neck Dissection | 2 | 2008 | 43 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 2011 | 1476 | 0.030 |
Why?
| Fluorouracil | 2 | 2004 | 61 | 0.030 |
Why?
| Photosensitivity Disorders | 2 | 2003 | 11 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2012 | 1696 | 0.030 |
Why?
| Infant | 2 | 2012 | 3829 | 0.030 |
Why?
| Lymph Node Excision | 2 | 2004 | 140 | 0.030 |
Why?
| Head | 1 | 2013 | 78 | 0.030 |
Why?
| Actins | 1 | 2013 | 132 | 0.030 |
Why?
| Neck | 1 | 2013 | 116 | 0.030 |
Why?
| Lymphocele | 1 | 2011 | 7 | 0.030 |
Why?
| Tissue Survival | 1 | 2011 | 12 | 0.030 |
Why?
| Antigens, Nuclear | 1 | 2011 | 24 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2011 | 76 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 55 | 0.030 |
Why?
| Administration, Topical | 1 | 2011 | 71 | 0.030 |
Why?
| Tissue Culture Techniques | 1 | 2011 | 46 | 0.030 |
Why?
| Treatment Outcome | 3 | 2011 | 5612 | 0.030 |
Why?
| Mice, Nude | 1 | 2011 | 284 | 0.020 |
Why?
| Neoplasms, Squamous Cell | 1 | 2010 | 9 | 0.020 |
Why?
| Time Factors | 2 | 2010 | 3210 | 0.020 |
Why?
| Granulation Tissue | 1 | 2010 | 12 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2010 | 55 | 0.020 |
Why?
| Myeloid Cells | 1 | 2010 | 38 | 0.020 |
Why?
| Tissue and Organ Harvesting | 1 | 2010 | 27 | 0.020 |
Why?
| Rats | 2 | 2009 | 3419 | 0.020 |
Why?
| Probability | 1 | 2010 | 177 | 0.020 |
Why?
| Endothelial Cells | 1 | 2011 | 294 | 0.020 |
Why?
| Graft Rejection | 1 | 2010 | 161 | 0.020 |
Why?
| Carcinoma | 1 | 2010 | 154 | 0.020 |
Why?
| Pilot Projects | 1 | 2011 | 807 | 0.020 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 72 | 0.020 |
Why?
| Thymine | 1 | 2008 | 11 | 0.020 |
Why?
| Centromere | 1 | 2008 | 17 | 0.020 |
Why?
| Microdissection | 1 | 2008 | 24 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2009 | 318 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2008 | 88 | 0.020 |
Why?
| Telomere | 1 | 2008 | 36 | 0.020 |
Why?
| Melanocytes | 1 | 2008 | 39 | 0.020 |
Why?
| Gene Dosage | 1 | 2008 | 92 | 0.020 |
Why?
| Iodine | 1 | 2007 | 12 | 0.020 |
Why?
| Genetic Markers | 1 | 2008 | 117 | 0.020 |
Why?
| Fluorescent Dyes | 1 | 2008 | 116 | 0.020 |
Why?
| Mice, Knockout | 1 | 2010 | 927 | 0.020 |
Why?
| Fatal Outcome | 1 | 2008 | 225 | 0.020 |
Why?
| Cluster Analysis | 1 | 2007 | 249 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1045 | 0.020 |
Why?
| Epithelial Cells | 1 | 2008 | 255 | 0.020 |
Why?
| Round Window, Ear | 1 | 2005 | 5 | 0.020 |
Why?
| Buffers | 1 | 2005 | 10 | 0.020 |
Why?
| Injections | 1 | 2005 | 61 | 0.020 |
Why?
| Rats, Inbred Lew | 1 | 2005 | 68 | 0.020 |
Why?
| Phosphates | 1 | 2005 | 51 | 0.020 |
Why?
| Prospective Studies | 1 | 2011 | 2606 | 0.020 |
Why?
| Drug Combinations | 1 | 2005 | 128 | 0.020 |
Why?
| Sodium Chloride | 1 | 2005 | 67 | 0.020 |
Why?
| Protein Isoforms | 1 | 2005 | 124 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2009 | 1664 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2010 | 2001 | 0.020 |
Why?
| Antibodies | 1 | 2005 | 178 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 232 | 0.010 |
Why?
| Disease-Free Survival | 1 | 2005 | 488 | 0.010 |
Why?
| Platelet Adhesiveness | 1 | 2003 | 13 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2007 | 1301 | 0.010 |
Why?
| Elastin | 1 | 2003 | 22 | 0.010 |
Why?
| Polytetrafluoroethylene | 1 | 2003 | 36 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 2003 | 72 | 0.010 |
Why?
| DNA Primers | 1 | 2003 | 225 | 0.010 |
Why?
| Radiotherapy | 1 | 2004 | 137 | 0.010 |
Why?
| Vascular Patency | 1 | 2003 | 92 | 0.010 |
Why?
| Radiotherapy, Adjuvant | 1 | 2003 | 66 | 0.010 |
Why?
| Dogs | 1 | 2003 | 216 | 0.010 |
Why?
| Up-Regulation | 1 | 2005 | 509 | 0.010 |
Why?
| Chemotherapy, Adjuvant | 1 | 2003 | 119 | 0.010 |
Why?
| Myocytes, Smooth Muscle | 1 | 2003 | 92 | 0.010 |
Why?
| Extracellular Matrix | 1 | 2003 | 111 | 0.010 |
Why?
| Graft Occlusion, Vascular | 1 | 2003 | 86 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2003 | 195 | 0.010 |
Why?
| Lymphatic Metastasis | 1 | 2003 | 256 | 0.010 |
Why?
| Young Adult | 1 | 2012 | 4318 | 0.010 |
Why?
| Thyroidectomy | 1 | 2003 | 103 | 0.010 |
Why?
| Stromal Cells | 1 | 2002 | 79 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 825 | 0.010 |
Why?
| Arkansas | 1 | 2004 | 2100 | 0.010 |
Why?
| Risk Assessment | 1 | 2003 | 1362 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2002 | 1141 | 0.010 |
Why?
| Pregnancy | 1 | 2003 | 2639 | 0.010 |
Why?
|
|
Fan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|